Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Clinical outcomes were evaluated in 82 dogs with B-cell lymphoma treated with adoptive T-cell therapy following cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Local targets link to admitted publications; unresolved targets remain external evidence.
Hematopoietic tumors
2020 · External reference
Retrospective analysis of factors affecting clinical outcome following CHOP-based chemotherapy in dogs with primary nodal diffuse large B-cell lymphoma
2018 · External reference
Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy
2012 · External reference
Optimized adoptive T-cell therapy for the treatment of residual mantle cell lymphoma
2012 · External reference
Veterinary cooperative oncology group—common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1
2016 · External reference
Canine multicentric lymphoma: diagnostic, treatment, and prognostic insights
2025 · External reference
Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol
2016 · External reference
Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)–a veterinary cooperative oncology group (VCOG) consensus document
2010 · External reference
Immortal time bias in observational studies of time-to-event outcomes: assessing effects of postmastectomy radiation therapy using the National Cancer Database
2018 · External reference
Comparison of CHOP-19 and CHOP-25 for treatment of peripheral nodal B-cell lymphoma in dogs: a European multicenter retrospective cohort study
2024 · External reference
